Folate Antagonists

Folate antagonists, or antifolates, are antimetabolite drugs that block the body's use of folic acid, a cofactor essential for synthesizing the nucleotides needed to make DNA. By inhibiting the enzyme dihydrofolate reductase and related folate-dependent steps, they starve dividing cells of the building blocks of replication. The prototype, aminopterin, produced the first remissions in childhood leukemia and launched modern cancer chemotherapy.

Definition

A folate antagonist is an antimetabolite that interferes with folate metabolism, classically by inhibiting dihydrofolate reductase, thereby depleting the reduced folate cofactors required for the synthesis of thymidylate and purines and so blocking DNA synthesis.

Scope

This entry covers the mechanism of folate antagonism, the central role of dihydrofolate reductase inhibition, the concept of folate-cofactor depletion in nucleotide synthesis, and the historical significance of the class. It is a pharmacology reference topic and does not address dosing, rescue strategies, or administration of any specific antifolate.

Core questions

• Why is folate essential for DNA synthesis?
• How does inhibiting dihydrofolate reductase block nucleotide production?
• What makes folate antagonists selective for dividing cells?
• Why was aminopterin historically significant?
• What mechanisms confer resistance to antifolates?

Key concepts

• Dihydrofolate reductase inhibition
• Reduced folate cofactor depletion
• Thymidylate and purine synthesis blockade
• Aminopterin and methotrexate as prototypes
• S-phase activity
• Reduced folate carrier and transport-based resistance

Mechanisms

Folate antagonists exploit the cell's dependence on reduced folates as one-carbon donors in nucleotide synthesis. By tightly inhibiting dihydrofolate reductase, classical antifolates prevent the regeneration of tetrahydrofolate, the active cofactor required to make thymidylate and purine nucleotides. The resulting depletion of these building blocks halts DNA synthesis, which makes the drugs most effective against cells in S phase and therefore cell-cycle specific. Some newer antifolates additionally target other folate-dependent enzymes such as thymidylate synthase. Resistance can arise through reduced cellular uptake via the reduced folate carrier, amplification or alteration of the target enzyme, and impaired intracellular retention of the drug (Farber & Diamond, 1948; Goodman & Gilman, 2018).

Clinical relevance

Folate antagonists are used across oncology and, at different exposures, in some non-malignant inflammatory conditions, and their mechanism underlies both their antiproliferative effect and their predictable toxicity to proliferating tissues. This topic conveys the pharmacologic basis of the class for educational appraisal; it is not a source of treatment or dosing advice.

Evidence & guidelines

The biochemistry of folate antagonism and dihydrofolate reductase inhibition is established textbook pharmacology, set out in standard references such as Goodman & Gilman. The clinical proof of concept rests on Farber and Diamond's 1948 report of temporary remissions in childhood acute leukemia with aminopterin, a landmark in the history of chemotherapy (Farber & Diamond, 1948; Chabner & Roberts, 2005).

History

In 1948 Sidney Farber and colleagues showed that the folate antagonist aminopterin could induce temporary remissions in children with acute leukemia, the first demonstration that a drug could drive back a disseminated cancer. This result, emerging from the study of folate's role in cell proliferation, established antifolates as the founding class of antimetabolite chemotherapy and inspired the later, more widely used congener methotrexate (Farber & Diamond, 1948; Chabner & Roberts, 2005).

Key figures

• Sidney Farber

Seminal works

• farber-1948
• chabner-roberts-2005

Frequently asked questions

How do folate antagonists stop cancer cells from dividing?

By blocking dihydrofolate reductase they deprive the cell of the reduced folate cofactors needed to make thymidylate and purines, so DNA synthesis cannot proceed and dividing cells are halted.

Why is aminopterin historically important?

Farber and Diamond's 1948 use of aminopterin produced the first temporary remissions in childhood leukemia, demonstrating that chemotherapy could work and opening the modern era of cancer drug treatment.